FOLD Amicus Therapeutics Inc.

Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2021.

Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 7374935. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

A replay of the call will be available for seven days beginning at 11:30 a.m. ET. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 7374935.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

CONTACT:

Investors:

Andrew Faughnan

Executive Director, Investor Relations

[email protected]

(609) 662-3809

Media:

Diana Moore

Head of Global Corporate Affairs & Communications

[email protected]

(609) 662-5079

FOLD–G



EN
27/07/2021

Underlying

FOLDAmicus Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amicus Therapeutics Inc.

 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Issues 2024 Environmental, Social, and Governance ...

Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year’s report highlights the strength of the Company’s corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensuring broad and equitable access...

March 20, 2024 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Present at Upcoming Investor Conferences in Mar...

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024 PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. Cowen 44th Annual Health Care Conference in Boston, MA, on Monday, March 4, 2024, at 11:10 a.m. E.T.Leerink Partners 2024 Global Biopharma Conference in Miami, FL on Monday, March 11, 2024, at 3:20 p.m. E.T. A live audio webcast of each presentation can also be accessed via the investors section of the A...

March 1, 2024 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Announces Full-Year 2023 Financial Results and Cor...

Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates 2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti™ + Opfolda™ in the U.S., U.K., and Germany Projecting 2024 Galafold® Revenue Growth of 11-16% at CER Anticipating Full-Year Non-GAAP Profitability in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases,...

February 28, 2024 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Announce Full Year 2023 Financial Results on Fe...

Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024 PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2023. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the ev...

February 15, 2024 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombilit...

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™ - Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease - PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced that WORLDSymposium™ has awarded Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) the 2024 New Treatment Award, which recognizes important achievements in advancing treatments for lysosomal diseases which have attai...

February 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch